Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
CA24463V1013
Thu, 06.06.2024
Defence Therapeutics Inc.
_________________________________________________________________
CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE
DEFENCE’S ACCUTOX PUBLISHED IN THE PRESTIGIOUS JOURNAL OF TRANSLATIONAL MEDICINE ITS PEER STUDY WITH PRECLINICAL DATA ON ACCUTOX AS AN ANTI-CANCER MOLECULE
Vancouver, BC, Canada, June 6th, 2024 - Defence Therapeutics Inc. ( [ … ]
Tue, 14.05.2024
Defence Therapeutics Inc.
CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE
DEFENCE THERAPEUTICS STRENGTHENS AND EXPANDS GLOBAL PATENT PROTECTION ON KEY TECHNOLOGIES
Vancouver, BC, Canada, May 14, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Canadian biopharmaceutical company developing novel immune-oncology [ … ]
Thu, 02.05.2024
Defence Therapeutics Inc.
_________________________________________________________________
CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE
PANCREACTIC CANCER: SUCCESFUL TRIAL AGAINST PANCREATIC CANCER WITH DEFENCE’S ARM-002 ANTI-CANCER VACCINE
Vancouver, BC, Canada, May 1st, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: D [ … ]
Tue, 23.04.2024
Defence Therapeutics Inc.
Vancouver, BC, Canada, April 23rd, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce that its second-generation ARMTM anti-cancer vaccine using AccuTOX®, called AR [ … ]
Wed, 17.04.2024
Defence Therapeutics Inc.
CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE
Vancouver, BC, Canada, April 17th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce that FMS Consult GmbH (“F [ … ]
Tue, 26.03.2024
Defence Therapeutics Inc.
CSE: DTC Börse Frankfurt: DTC OTCQB: DTCFF PRESSEMITTEILUNG
ERFOLGE VON DEFENCE BEI SEINEM ACCUTOX®-ARMTM-VAKZIN ZUR KREBSBEKÄMPFUNG FÜHREN ZUR ENTWICKLUNG EINES WIRKUNGSVOLLEN ARM-002TM-KREBSIMPFSTOFFS DER ZWEITEN GENERATION
Vancouver, British Columbia, Kanada, den 26. März 2024 – Defence Therapeutics Inc. („Defence“ oder das „Untern [ … ]
Tue, 26.03.2024
Defence Therapeutics Inc.
_________________________________________________________________
CSE: DTC FSE: DTC OTCQB: DTCFF PRESS RELEASE
DEFENCE’S SUCCESSFUL RESULTS ON ITS ACCUTOX® ANTI-CANCER ARMTM VACCINE CREATES A POTENT SECOND-GENERATION ANTI-CANCER ARM-002TM VACCINE
Vancouver, BC, Canada, March 26th, 2024 - Defence Therapeutics Inc. (“Defence” or [ … ]
Mon, 04.03.2024
Defence Therapeutics Inc.
_________________________________________________________________
CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE
DEFENCE THERAPEUTICS AWARDED BROAD U.S. PATENT COVERING ITS PIONEERING CANCER-KILLING ACCUTOX® TECHNOLOGY
Vancouver, BC, Canada, March 4th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceu [ … ]
Wed, 10.01.2024
Defence Therapeutics Inc.
_________________________________________________________________
CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE
DEFENCE’S ACCUTOX® IMPAIRS LUNG CANCER GROWTH
Vancouver, BC, Canada, January 10th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), one of the leading Canadian biotechno [ … ]